Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis

Paul S. Tlucek, Donald U. Stone

Research output: Contribution to journalArticle

Abstract

Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.

Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.

Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.

Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.

Original languageEnglish (US)
Pages (from-to)90-91
Number of pages2
JournalCornea
Volume31
Issue number1
StatePublished - Jan 1 2012
Externally publishedYes

Fingerprint

Scleritis
Rheumatoid Arthritis
Tumor Necrosis Factor-alpha
Therapeutics
Certolizumab Pegol

Keywords

  • Certolizumab
  • Scleritis
  • Tumor necrosis factor alpha inhibitor

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Tlucek, P. S., & Stone, D. U. (2012). Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. Cornea, 31(1), 90-91.

Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. / Tlucek, Paul S.; Stone, Donald U.

In: Cornea, Vol. 31, No. 1, 01.01.2012, p. 90-91.

Research output: Contribution to journalArticle

Tlucek, PS & Stone, DU 2012, 'Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis', Cornea, vol. 31, no. 1, pp. 90-91.
Tlucek, Paul S. ; Stone, Donald U. / Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis. In: Cornea. 2012 ; Vol. 31, No. 1. pp. 90-91.
@article{991ddc8824374a14b3af115368c45d29,
title = "Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis",
abstract = "Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.",
keywords = "Certolizumab, Scleritis, Tumor necrosis factor alpha inhibitor",
author = "Tlucek, {Paul S.} and Stone, {Donald U.}",
year = "2012",
month = "1",
day = "1",
language = "English (US)",
volume = "31",
pages = "90--91",
journal = "Cornea",
issn = "0277-3740",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Certolizumab pegol therapy for rheumatoid arthritis-associated scleritis

AU - Tlucek, Paul S.

AU - Stone, Donald U.

PY - 2012/1/1

Y1 - 2012/1/1

N2 - Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.

AB - Conclusions: Certolizumab pegol may successfully treat RAassociated scleritis, even in a patient who has not tolerated therapy with other tumor necrosis factor alpha antagonists or in whom that treatment has failed.Results: Six months after beginning the new therapy, it was welltolerated and the patient's RA and scleritis were quiescent.Purpose: To report the successful treatment of rheumatoid arthritis (RA)-associated scleritis with the tumor necrosis factor alpha antagonist certolizumab pegol.Methods: Retrospective case report of therapeutic interventions for a 47-year-old woman with scleritis and RA. After not tolerating treatment with other tumor necrosis factor alpha inhibitors and rituximab, or after that treatment failed, certolizumab pegol was administered in an attempt to achieve better control of her disease process.

KW - Certolizumab

KW - Scleritis

KW - Tumor necrosis factor alpha inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84856505045&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856505045&partnerID=8YFLogxK

M3 - Article

C2 - 21941174

AN - SCOPUS:84856505045

VL - 31

SP - 90

EP - 91

JO - Cornea

JF - Cornea

SN - 0277-3740

IS - 1

ER -